Despite significant progress in medicinal chemistry and life sciences research, drug discovery and development remain slow and expensive, taking on average approximately 15 years and US$2 billion to ...

A new study published in Cell has unveiled a first-of-a-kind optogenetic screening platform, developed by scientists at Integrated Biosciences, a biotechnology company integrating optogenetics, ...

The year 2025 marked a major leap for AI in health care, with breakthroughs in drug discovery, diagnostics, genomics and ...

In drug discovery, virtual screening is a fast and cost-effective way of narrowing down vast chemical libraries to identify the most promising hits, reducing synthesis and testing requirements while ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Integrated Biosciences, a biotechnology company integrating optogenetics, chemistry and AI to discover small molecule therapeutics for age-related diseases, ...

This article and associated images are based on a poster originally authored by Lin Chen, Vincent Blay, Pedro J. Ballester and Douglas R. Houston and presented at ELRIG Drug Discovery 2025 in ...

In this webinar, Robert Lowrey and David Siderovski will discuss novel AI-driven drug discovery approaches targeting ...

Artificial Intelligence (AI) and machine learning are transforming the worlds of biotechnology and pharma, particularly in the arena of drug discovery. Leveraging the rise of large datasets and ...

Artificial, Inc (“Artificial”), a technology company providing cloud-based solutions to streamline laboratory operations and accelerate life science discoveries, today announced proof of concept data ...

Experience the forefront of pharmaceutical innovation as Labroots and the Drug Discovery and Development planning committee host the 9th Annual Drug Discovery & Development Virtual Event on February ...